Filtered By:
Condition: Atrial Fibrillation
Procedure: Heart Transplant

This page shows you your search results in order of relevance. This is page number 5.

Order by Relevance | Date

Total 240 results found since Jan 2013.

Novel Oral Anticoagulants in Patients with Continuous Flow Left Ventricular Assist Devices
The gold standard for anticoagulation in patients with continuous flow left ventricular assist device (CF-LVADs) is warfarin. However, many patients fail warfarin therapy due to thromboembolic and bleeding events. Warfarin requires regular monitoring and dosage adjustments, and is associated with significant patient time outside recommended therapeutic INR range. Novel oral anticoagulation (NOAC) has been shown to be non-inferior compared to warfarin in stroke prevention with less intracranial hemorrhage in patients with atrial fibrillation.
Source: The Journal of Heart and Lung Transplantation - March 16, 2019 Category: Transplant Surgery Authors: V. Parikh, U. Parikh, A.M. Ramirez, H. Lamba, J. George, S. Fedson, F. Cheema, A. Civitello, A. Nair, A. Shafii, G. Loor, T. Rosengart, O. Frazier, J. Morgan, R. Delgado Tags: 1072 Source Type: research

Prognostic value of left atrial strain in patients with moderate asymptomatic mitral regurgitation
AbstractFor patients with asymptomatic mitral regurgitation (MR), the criteria identifying the groups at higher-risk and their clinical outcome are still uncertain. Therefore, in these patients, optimal time of surgery remains controversial. The purpose of this study was to compare left atrial (LA) strain to other echocardiographic left ventricular (LV) and LA parameters for the prediction of cardiovascular outcomes in patients with moderate asymptomatic MR. We enrolled 395 patients with primary degenerative moderate asymptomatic MR. Exclusion criteria were: history of atrial fibrillation, myocardial infarction, heart fail...
Source: The International Journal of Cardiovascular Imaging - April 9, 2019 Category: Radiology Source Type: research

Pentraxin 3 in Cardiovascular Disease
Giuseppe Ristagno1*, Francesca Fumagalli1, Barbara Bottazzi2, Alberto Mantovani2,3,4, Davide Olivari1, Deborah Novelli1 and Roberto Latini1 1Department of Cardiovascular Research, Mario Negri Institute for Pharmacological Research IRCCS, Milan, Italy 2Humanitas Clinical and Research Center-IRCCS, Milan, Italy 3Humanitas University, Milan, Italy 4The William Harvey Research Institute, Queen Mary University of London, London, United Kingdom The long pentraxin PTX3 is a member of the pentraxin family produced locally by stromal and myeloid cells in response to proinflammatory signals and microbial moieties. The p...
Source: Frontiers in Immunology - April 16, 2019 Category: Allergy & Immunology Source Type: research

An artificial intelligence-enabled ECG algorithm for the identification of patients with atrial fibrillation during sinus rhythm: a retrospective analysis of outcome prediction
Publication date: Available online 1 August 2019Source: The LancetAuthor(s): Zachi I Attia, Peter A Noseworthy, Francisco Lopez-Jimenez, Samuel J Asirvatham, Abhishek J Deshmukh, Bernard J Gersh, Rickey E Carter, Xiaoxi Yao, Alejandro A Rabinstein, Brad J Erickson, Suraj Kapa, Paul A FriedmanSummaryBackgroundAtrial fibrillation is frequently asymptomatic and thus underdetected but is associated with stroke, heart failure, and death. Existing screening methods require prolonged monitoring and are limited by cost and low yield. We aimed to develop a rapid, inexpensive, point-of-care means of identifying patients with atrial ...
Source: The Lancet - August 2, 2019 Category: General Medicine Source Type: research

Comparison of Healthcare Resource Utilization and Costs between Rivaroxaban and Warfarin for Nonvalvular Atrial Fibrillation in a Skilled Nursing Facility Setting
ConclusionIn this SNF setting, HCRU and costs were lower among patients with NVAF who were experienced users of rivaroxaban compared with those who were experienced users of warfarin. These findings may help inform clinical decision making to reduce the economic burden of NVAF among older adults in SNFs.
Source: Drugs and Aging - March 8, 2020 Category: Geriatrics Source Type: research

Left Atrial Volume after Heart Transplantation - A Predictor of Outcomes?
The left atrium (LA) in heart transplant (HT) recipients is a surgically created chamber from variable portions of donor and recipient. In the non-HT patients there is strong evidence that left atrial volume (LAV) is a robust predictor of cardiovascular outcomes such as atrial fibrillation, stroke, heart failure and cardiovascular death. Thus, we thought to 1) characterize LA size in HT recipients and 2) investigate the implications of “new” LA volume on HT outcomes.
Source: The Journal of Heart and Lung Transplantation - March 31, 2020 Category: Transplant Surgery Authors: Y. Peled, J. Lavee, E. Ram, Y. Kassif, L. Sternik, E. Schwammenthal, R. Klempfner, B. Tzur Tags: (614) Source Type: research

The hospitalizations in hypertrophic cardiomyopathy: “the dark side of the moon”.
Hypertrophic cardiomyopathy (HCM) is a myocardial disease characterized by left ventricular hypertrophy not solely explainable by abnormal loading condition [1,2]. Patients with HCM show a different clinical course, ranging from an asymptomatic status, with no adverse events and normal or extended longevity, to a symptomatic condition in which several disease complications can occur [3]. Among HCM patients which experience disease progression, 3 different pathways have been identified: refractory heart failure (HF), requiring surgical myectomy/alcohol ablation (obstructive HCM, OHCM) or heart transplant (non-obstructive HC...
Source: International Journal of Cardiology - August 14, 2020 Category: Cardiology Authors: Emanuele Monda, Giuseppe Limongelli Tags: Editorial Source Type: research

The hospitalizations in hypertrophic cardiomyopathy: “The dark side of the moon”
Hypertrophic cardiomyopathy (HCM) is a myocardial disease characterized by left ventricular hypertrophy not solely explainable by abnormal loading condition [1,2]. Patients with HCM show a different clinical course, ranging from an asymptomatic status, with no adverse events and normal or extended longevity, to a symptomatic condition in which several disease complications can occur [3]. Among HCM patients which experience disease progression, 3 different pathways have been identified: refractory heart failure (HF), requiring surgical myectomy/alcohol ablation (obstructive HCM, OHCM) or heart transplant (non-obstructive HC...
Source: International Journal of Cardiology - August 14, 2020 Category: Cardiology Authors: Emanuele Monda, Giuseppe Limongelli Tags: Editorial Source Type: research

229 Long Term Risk of Stroke in Patients with New Post-Operative Atrial Fibrillation After Liver Transplantation
New-onset postoperative atrial fibrillation (POAF) is common in patients undergoing liver transplantation (LT). To date, studies have not evaluated whether POAF in LT recipients increases the risk of cerebrovascular events (CVE).
Source: Heart, Lung and Circulation - November 8, 2020 Category: Cardiology Authors: A. Enayati, A. Koshy, O. Farouque, P. Gow, H. Han, B. Cailes, L. Weinberg, A. Testro, H. Lim, A. Teh Source Type: research

Hypertrophic cardiomyopathy considerations for the managed care pharmacist
Am J Manag Care. 2021 Apr;27(6 Suppl):S118-S125. doi: 10.37765/ajmc.2021.88629.ABSTRACTHypertrophic cardiomyopathy (HCM) is often seen in patients as an autosomal dominant genetic heart disease with a variable clinical course. It is characterized by left ventricular hypertrophy, and with some patients, there is no evidence of a genetic etiology or presence of HCM in family members. Young age at diagnosis and the presence of a pathogenic or likely pathogenic sarcomere variant predict greater lifelong risk for stroke, heart failure, ventricular arrhythmia, atrial fibrillation, or mortality. Most individuals affected with HCM...
Source: The American Journal of Managed Care - April 16, 2021 Category: Health Management Authors: Patty Taddei-Allen Source Type: research

Clinical characteristics and outcomes in childhood-onset hypertrophic cardiomyopathy
ConclusionPatients with childhood-onset HCM are more likely to have sarcomeric disease, carry a higher risk of life-threatening ventricular arrythmias, and have greater need for advanced HF therapies. These findings provide insight into the natural history of disease and can help inform clinical risk stratification.
Source: European Heart Journal - March 26, 2021 Category: Cardiology Source Type: research

IJERPH, Vol. 18, Pages 11302: Review of Deep Learning-Based Atrial Fibrillation Detection Studies
Rajendra Acharya Atrial fibrillation (AF) is a common arrhythmia that can lead to stroke, heart failure, and premature death. Manual screening of AF on electrocardiography (ECG) is time-consuming and prone to errors. To overcome these limitations, computer-aided diagnosis systems are developed using artificial intelligence techniques for automated detection of AF. Various machine learning and deep learning (DL) techniques have been developed for the automated detection of AF. In this review, we focused on the automated AF detection models developed using DL techniques. Twenty-four relevant articles published in intern...
Source: International Journal of Environmental Research and Public Health - October 28, 2021 Category: Environmental Health Authors: Fatma Murat Ferhat Sadak Ozal Yildirim Muhammed Talo Ender Murat Murat Karabatak Yakup Demir Ru-San Tan Udyavara Rajendra Acharya Tags: Review Source Type: research